Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-06-14
2011-06-14
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S362000
Reexamination Certificate
active
07960388
ABSTRACT:
Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
REFERENCES:
patent: 4238497 (1980-12-01), Black et al.
patent: 4443466 (1984-04-01), Karjalainen et al.
patent: 4927942 (1990-05-01), Speranza et al.
patent: 7157464 (2007-01-01), Pennell et al.
patent: 7449576 (2008-11-01), Pennell et al.
patent: 7524845 (2009-04-01), Zhang et al.
patent: 7629344 (2009-12-01), Li et al.
patent: 7777035 (2010-08-01), Zhang et al.
patent: 2004/0082571 (2004-04-01), Pennell et al.
patent: 2004/0162282 (2004-08-01), Pennell et al.
patent: 2005/0234034 (2005-10-01), Pennell et al.
patent: 2005/0256130 (2005-11-01), Pennell et al.
patent: 2006/0074121 (2006-04-01), Chen et al.
patent: 2006/0106218 (2006-05-01), Pennell et al.
patent: 2007/0010523 (2007-01-01), Zhang et al.
patent: 2007/0010524 (2007-01-01), Zhang et al.
patent: 2008/0058341 (2008-03-01), Zhang et al.
patent: WO 03/105853 (2003-12-01), None
patent: WO 2005/056015 (2005-06-01), None
patent: WO 2005/084667 (2005-09-01), None
patent: WO 2007/027734 (2007-03-01), None
patent: WO 2007/027734 (2007-03-01), None
Melter et al, Current Opinion in Organ Transplantation, vol. 7, p. 77-84 (2002).
Bedke, et al., “Beneficial Effects of CCR1 Blockade on the Progression of Chronic Renal Allograft Damage,”Am J Transplant, Mar. 2007; 7(3): pp. 527-537, Epub Jan. 4, 2007.
Borregaard et al., “Evaluation of the effect of the specific CCR1 antagonist CP-481715 on the clinical and cellular responses observed following epicutaneous nickel challenge in human subjects”Contact Dermatitis, 2008 59 (4): pp. 212-219.
Clucas, et al., “Phase I Evaluation of the Safety, Pharmacokinetics and Pharmacodynamics of CP-481,715,”Clin Pharnacokinet, 2007 46(9), pp. 757-766.
Gladue, et al., “Current Status of CCR1 Antagonists in Clinical Trials,”Chemokine Biology—Basic Research and Clinical Application, vol. II, 2007 pp. 103-113.
Gladue, et al., “The Human Specific CCR1 Antagonist CP-481,715 Inhibits Cell Infiltration and Inflammatory Responses in Human CCR1 Transgenic Mice,”The Journal of Immunology, 2006, vol. 176, pp. 3141-3148.
Gladue, et al., “CP-481,715, a Potent and Selective CCR1 Antagonist with Potential Therapeutic Implications for Inflammatory Diseases,”The Journal of Biological Chemistry, 2003, vol. 278, No. 42, pp. 40473-40480.
Gladue, et al., “CCR1 Antagonists: What Have We Learned From Clinical Trials,”Curr Top Med Chem., Jun. 11, 2010 [Epub ahead of print].
Yun, et al, “Combined Blockade of the Chemokine Receptors CCR1 and CCR5 Attenuates Chronic Rejection,”Circulation2004, vol. 109, pp. 932-937.
Bendele, A. et al., “Animal Models of Arthritis: Relevance to Human Disease,”Toxicologic Pathology, 1999, vol. 27, No. 1, pp. 134-142.
Bendele, A, et al., “Efficacy of Sustained Blood Levels of Interleukin-1 Receptor Antagonist in Animal Models of Arthritis,”Arthritis&Rheumatism, Mar. 1999, vol. 42, No. 3, pp. 498-506.
Dairaghi, D.J. et al., “Chemokine Receptor CCR3 Function Is Highly Dependent on Local pH and Ionic Strength,”The Journal of Biological Chemistry, Nov. 7, 1997, vol. 272, No. 45, pp. 28206-28209.
Dairaghi, D.J. et al., “HHV8-encoded vMIP-I Selectivity Engages Chemokine Receptor CCR8,”The Journal of Biological Chemistry, Jul. 30, 1999, vol. 274, No. 31, pp. 21569-21574.
Gladue et al., Chemokine Biology, vol. II, p. 103-113 (2007).
Hesselgesser, J. et al., “Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor,”The Journal of Biological Chemistry, Jun. 19, 1998, vol. 273, No. 25, pp. 15687-15692.
International Search Report mailed on Aug. 6, 2008, for International Application No. PCT/US08/64374 filed on May 21, 2008, 2 pages.
Jones, J. et al., “British Society of Gastroenterology guidelines for the management of the irratable bowel syndrome” Division of Gastroenterology, University Hospital, Nottingham, UK, 19 pages.
Liang, M. et al., “Identification and Characterization of a Potent, Selective, and Orally Active Antagonists of the CC Chemokine Receptor-1,”The Journal of Biological Chemistry, Jun. 23, 2000, vol. 275, No. 25, pp. 19000-19008.
Liang, M. et al., “Species Selectivity of a small molecule antagonist for the CCR1 chemokine receptor,”European Journal of Pharmacology, 2000, vol. 389, pp. 41-49.
Ng, H.P. et al., “Discovery of Novel Non-Peptide CCR1 Receptor Antagonists,”Journal of Medicinal Chemistry, 1999, vol. 42, No. 22, pp. 4680-4694.
Palmer, A.M., “Pharmacotherapy for Alzheimer's disease: progress and prospects,”Trends in Pharmacological Sciences, Sep. 2002, vol. 23, No. 9, pp. 426-433.
Penfold, M.E.T. et al., “Cytomegalovirus encodes a potent a chemokine,”Proc. Natl. Acad. Sci. USA, Aug. 1999, vol. 96, pp. 9839-9844.
Podolin, P.L. et al. “A Potent and Selective Nonpeptide Antagonist of CXCR2 Inhibits Acute and Chronic Models of Arthritis in the Rabbit,”The Journal of Immunology, 2002, vol. 169, pp. 6435-6444.
Trentham, D.E. et al., “Autoimmunity to Type II Collagen: An Experimental Model of Arthritis,”The Journal of Experimental Medicine, 1977, vol. 146, pp. 857-868.
Li Lianfa
Pennell Andrew M.K.
Zhang Penglie
Bernhardt Emily
ChemoCentryx, Inc.
Kilpatrick Townsend & Stockton LLP
LandOfFree
3-(imidazolyl)-pyrazolo[3,4-b]pyridines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-(imidazolyl)-pyrazolo[3,4-b]pyridines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-(imidazolyl)-pyrazolo[3,4-b]pyridines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2657312